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background:  The PRIVATE-ATLANTIC a prespecified substudy of the randomized double blind placebo controlled ATLANTIC Trial aimed 
to assess platelet inhibition of pre-hospital versus in-hospital initiation of ticagrelor therapy.
methods:  We measured platelet inhibition in 37 patients by a centralized measured of VASP-PRI in a series of biological measurements 
(before angiogram (T1)), after PCI (T2)), 1 hour after PCI (T3), 6 hours after PCI (T4) and before the next study drug administration (T5). 
VerifyNow measurement and measure of the ticagrelor metabolite were also performed.
Results:  The time difference between the two groups in term of initiation of ticagrelor therapy was 41 minutes. When considering the 
whole population, ticagrelor administration led to a stepwise decrease in platelet reactivity over time as measured by the VASP-PRI or 
PRU; p<0.0001 for both for the global effect). However, platelet inhibition was not different according to treatment strategy, at the time 
of evaluation of reperfusion (T1), the primary endpoint of the trial, when measured by VASP-PRI (89.8% vs. 93.9%; for pre-hospital and 
in-hospital administration respectively, p= 0.18) or by the PRU (239 vs. 241, p= 0.82). Differences started to appears at (T2) (80.5% vs. 
93.8%, p= 0.03 for VASP-PRI and 245 vs. 282; p= 0.38 for PRU) and were maximum at T3 (46.2% vs. 86.9%;, p= 0.12 and 65 vs. 207; 
p= 0.21) but were not significant due to lack of power (p value significant <0.01 for Bonferroni correction). T3 was the moment of the 
evaluation of the post PCI ST resolution, the secondary endpoint of the trial, which was reduced by pre-hospital administration (p=0.05). 
Ticagrelor metabolites were very low at T1 (2.50 ng/mL for AR-C124910XX and 1.96 ng/mL for Ticagrelor) when compared to the stable 
levels at T5 (152 ng/mL for AR-C124910XX and 524 ng/mL for AR-C133913XX).
conclusion:  As compared to in-hospital administration, pre-hospital ticagrelor administration did not improve platelet inhibition at the time 
of initial angiogram due to the absence of significant level of active metabolite. The maximum difference in platelet inhibition was detected 
at the end of PCI. These results are supportive of the results of the ATLANTIC Trial.
